Antigenics Inc. (AGEN) Close to Commercial Business Start
The most important management announcement during declaration of business results for the Most Recent Quarter is that the company is set to make a commercial launch in the anti-cancer segment of the Russian market during the second half of 2008. The company has made impressive business progress during the last four quarters and during the Most Recent Quarter as well. Annual losses have been slashed from about $52 million a year ago to about $37 million. Cash depletion has been halved from the 2006 level of $50 million. Cost containment is not a general strength of the Biotechnology & Drugs…